TGA Issues Guidance on Combination and Boundary Products for Pharmaceutical Companies in APAC

Key Takeaways

• TGA defines combination products as therapeutic goods combining medicines, medical devices, or biologicals
• Boundary products have attributes of multiple product types and require specific regulatory classification
• All combination and boundary products must be listed or registered unless specifically exempt

---

TGA Clarifies Regulatory Framework for Combination and Boundary Products

Australia’s Therapeutic Goods Administration (TGA) has issued updated guidance on the regulatory classification of combination and boundary products, providing critical clarity for pharmaceutical and medical device companies operating in the Asia-Pacific region.

IntelligenceRegulatory Impact▾

TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Understanding Combination Products

Combination products represent therapeutic goods that integrate elements from multiple categories including medicines, medical devices, or biologicals. The TGA specifically highlights pre-filled syringes and medicine-releasing stents as prime examples of these hybrid products that require specialized regulatory consideration.

These products present unique regulatory challenges as they don’t fit neatly into traditional therapeutic good categories, necessitating careful evaluation of their primary mode of action and constituent components.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Boundary Products Defined

Boundary products, distinct from combination products, are therapeutic goods that exhibit characteristics spanning two or more product types. Common examples include nasal decongestion products and eye lubricating products, which may function as both medicines and medical devices depending on their formulation and intended use.

The classification of boundary products often depends on their primary mechanism of action and the claims made by manufacturers regarding their therapeutic benefits.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Regulatory Requirements

Unless specifically exempt or excluded under TGA regulations, both combination and boundary products must undergo the standard listing or registration process. This requirement ensures that all therapeutic goods entering the Australian market meet appropriate safety, quality, and efficacy standards.

Manufacturers must carefully assess their products against TGA criteria to determine the appropriate regulatory pathway and ensure compliance with Australian therapeutic goods legislation.

IntelligenceStrategic Takeaways▾

TGA defines combination products as therapeutic goods combining medicines, medical devices, or biologicals Boundary products have attributes of multiple product types and require specific regulatory classification All combination and boundary products must be listed or registered unless specifically exempt

Industry Impact

This guidance provides essential clarity for companies developing innovative therapeutic products that blur traditional regulatory boundaries. The clear definitions help streamline the approval process and reduce regulatory uncertainty for manufacturers seeking market access in Australia.

---

Frequently Asked Questions

What is the difference between combination and boundary products?

Combination products combine elements of medicines, medical devices, or biologicals, while boundary products have attributes of multiple product types but aren’t necessarily combined products.

Do all combination and boundary products require TGA registration?

Yes, unless specifically exempt or excluded, all combination and boundary products must be listed or registered with the TGA before market entry.

How should companies determine the regulatory pathway for their products?

Companies should assess their product’s primary mode of action and constituent components against TGA criteria, and may consult with TGA directly for complex classification decisions.

Related coverage

• TGA Australia drug approval pharmaceutical: what the regulator is
• Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India: Strategic implications for pharma BD teams
• The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains